



HEALTHCARE

The Cardiovascular Market Outlook to 2013

Competitive landscape, global market analysis and pipeline analysis

 [Table of Contents](#)

Copyright © 2008 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any
purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of
Business Insights. Business Insights Ltd accepts no liability for the accuracy or
completeness of the information, advice or comment contained in this Management
Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of
publication, no responsibility can be accepted by Business Insights Ltd for its
completeness or accuracy.

Table of Contents

The Cardiovascular Market Outlook to 2013

Executive summary	12	
Overview and epidemiology of cardiovascular disorders	12	
Global market analysis	12	
Pipeline analysis	13	
Competitive landscape	14	
Chapter 1	Scope and methodology	16
Scope		16
Methodology		17
Chapter 2	Overview and epidemiology of cardiovascular disorders	20
Summary		20
Introduction		20
Predisposing factors		21
Risk factors		24
Hypertension		24
Diagnosis, treatment and management		25
Epidemiology		27
Forecast epidemiology		28
Dyslipidemia		29
Diagnosis, treatment and management		30
Epidemiology		33
Forecast epidemiology		34
Cardiovascular diseases		35
Arteriosclerosis/atherosclerosis		35
Thrombosis		35
Cardiac arrhythmias		35
Myocardial infarction		36
Acute coronary syndrome (ACS)		36
Congestive heart failure (CHF)		36

Coronary artery disease (CAD)	36
Peripheral artery disease (PAD)	36
Pulmonary hypertension	37
Angina pectoris	37
Stroke	37
Epidemiology	38
Forecast epidemiology	39

Chapter 3 Global market analysis 42

Summary	42
Introduction	43
Market analysis by country	44
Licensing Trends	45
Market analysis by drug class	46
Leading brands dynamics	48
Cardiovascular sales forecast to 2013	49
Key events in the cardiovascular market	50
Therapeutic substitution causing decline in sales of leading hypercholesterolemia drugs	50
Genericization in the leading classes of hypertension drugs	51
Tekturna/Rasilez launch slower than expected	52
Generic Plavix in Germany represents moderate risk	52
Regulatory delay for Prasugrel improve US Plavix outlook	53
Safety concerns on ESAs to impact the multibillion dollar EPO franchises	54
Anti-hypertensive treatments	54
Introduction	54
Anti-hypertensives drug classes	55
Leading treatment brands by drug class	57
Key brands analysis	59
Norvasc	59
Diovan	59
Cozaar	60
Sales forecast to 2013	62
Anti-dyslipidemics	63
Introduction	63
Anti-dyslipidemics drug classes	64
Leading treatment brands by drug class	65
Key brands analysis	66
Lipitor	66
Vytorin	68
Crestor	69
Sales forecast to 2013	72
Anti-thrombotics treatments	73

Introduction	73
Anti-thrombotics drug classes	74
Leading treatment brands by drug class	75
Key brands analysis	76
Lovenox	76
Plavix	78
Sales forecast to 2013	80
Hematological preparations	81
Introduction	81
Market analysis by drug class	82
Leading treatment brands by drug class	82
Key brands analysis	83
Aranesp	83
Sales forecast to 2013	85
Cardiac therapies	86
Introduction	86
Market analysis by drug class	86
Leading treatment brands by drug class	88
Sales forecast to 2013	89
Other cardiovascular agents	90
Introduction	90
Leading brands by drug class	90
Key brands analysis	91
Tracleer	91
Sales forecast to 2013	93

Chapter 4 Pipeline analysis 96

Summary	96
Introduction	97
Key events in the development of the cardiovascular pipeline	98
Merck's Cordaptive/Tredaptive facing regulatory delay owing to safety concerns	98
Persistent interest in drugs which increase HDL cholesterol levels	99
Mipomersen from Genzyme may become a novel option for high cholesterol	99
New treatments drive robust growth of the anticoagulants class	100
Multaq may become the gold-standard as first-line treatment of chronic atrial fibrillation	100
Bayer Schering/J&J's Xarelto demonstrates best in class characteristics	101
Cytos Biotechnology reports encouraging results for its hypertension vaccine	101
Novel reperfusion agent from Neurobiological Technologies presents significant commercial opportunity	102
Cardiovascular pipeline	104
Leading drugs in development	106
Profiles of key pipeline products	107
Recently marketed drugs	107

	Letairis	107
	Tekturna/Rasilez	108
Drugs in registration		110
	Effient	110
	Multaq	111
	Xarelto	113
	TriLipix	114
	Pradaxa/Rendix	116
Drugs in Phase III clinical studies		117
	Apixaban	117
	Cangrelor	119
	SCH 530348	120
	Ticagrelor	121
Drugs in Phase II clinical studies		123
	E5555	123
Pipeline forecast		124

Chapter 5 Competitive Landscape 128

Summary		128
Introduction		129
Sales performance of leading players		129
Detailed analysis of leading cardiovascular players		133
Pfizer		133
	Overview	133
	Sales focus by drug class	134
	Marketed product portfolio	135
	R&D pipeline analysis	138
	Strategic and growth analysis	139
Sanofi-Aventis		141
	Overview	141
	Sales focus by drug class	141
	Marketed product portfolio	144
	R&D pipeline analysis	146
	Strategic and growth analysis	148
Merck		150
	Overview	150
	Sales focus by drug class	150
	Marketed product portfolio	152
	R&D pipeline analysis	153
	Strategic and growth analysis	154
Novartis		155
	Overview	155
	Sales focus by drug class	155
	Marketed product portfolio	158
	R&D pipeline analysis	159
	Strategic and growth analysis	160

Amgen		162
	Overview	162
	Sales focus by drug class	162
	Marketed product portfolio	163
	R&D pipeline analysis	164
	Strategic and growth analysis	164
AstraZeneca		165
	Overview	165
	Sales focus by drug class	165
	Marketed product portfolio	168
	R&D pipeline analysis	169
	Strategic and growth analysis	171
Bristol-Myers Squibb		171
	Overview	171
	Sales focus by drug class	172
	Marketed product portfolio	174
	R&D pipeline analysis	175
	Strategic and growth analysis	176
Johnson and Johnson		178
	Overview	178
	Sales focus by drug class	178
	Marketed product portfolio	179
	R&D pipeline analysis	180
	Strategic and growth analysis	180
Daiichi Sankyo		182
	Overview	182
	Sales focus by drug class	182
	Marketed product portfolio	183
	R&D pipeline analysis	184
	Strategic and growth analysis	185
GlaxoSmithKline		186
	Overview	186
	Sales focus by drug class	186
	Marketed product portfolio	188
	R&D pipeline analysis	189
	Strategic and growth analysis	190

Chapter 6 Appendix 192

Glossary	193
Index	197

List of Figures

Figure 2.1:	Cardiovascular disease etiology	23
Figure 2.2:	Cardiovascular risk factors	24
Figure 2.3:	Definition and classification of hypertension	25
Figure 2.4:	Hypertension - treatment options	26
Figure 2.5:	Types of lipoproteins	30
Figure 2.6:	Interpretation of blood lipid levels	31
Figure 2.7:	LDL levels and therapy patterns	32
Figure 3.8:	Global cardiovascular market share by geography (\$m), 2007	44
Figure 3.9:	Global sales of types of cardiovascular brands (\$bn), 2006–07	45
Figure 4.10:	Prevailing R&D approaches, 2008	98
Figure 4.11:	Cardiovascular pipeline by indication and stage of development, 2008	104
Figure 4.12:	Leading recently marketed and late-stage R&D products in the cardiovascular market, 2008	106
Figure 5.13:	Sales of key players in the cardiovascular market, (\$m), 2007	130
Figure 5.14:	Forecast sales of key players in the cardiovascular market, (\$m), 2007	131
Figure 5.15:	Market share of key players by sales value, 2013	132
Figure 5.16:	Pfizer cardiovascular sales by drug class, (\$bn), 2007	134
Figure 5.17:	Sanofi's cardiovascular sales by drug class, (\$bn), 2007	142
Figure 5.18:	Merck cardiovascular sales by drug class, (\$bn), 2007	151
Figure 5.19:	Novartis' cardiovascular sales by drug class, (\$bn), 2007	157
Figure 5.20:	Amgen's cardiovascular sales by drug class, (\$bn), 2007	163
Figure 5.21:	AstraZeneca's cardiovascular sales by drug class, (\$bn), 2007	167
Figure 5.22:	BMS's cardiovascular sales by drug class, (\$bn), 2007	173
Figure 5.23:	J&J's cardiovascular sales by drug class, (\$bn), 2007	178
Figure 5.24:	Daiichi Sankyo's cardiovascular sales by drug class, (\$bn), 2007	182
Figure 5.25:	GSK's cardiovascular sales by drug class, (\$bn), 2007	187

List of Tables

Table 2.1:	Estimated prevalence of cardiovascular disorders across seven major markets (in thousands), 2007	21
Table 2.2:	Estimated prevalence of hypertension across the seven major markets (in thousands), 2007	27
Table 2.3:	Forecast epidemiology of hypertension across seven major markets (in thousands), 2007–2013	28
Table 2.4:	Estimated prevalence of dyslipidemia across the seven major markets (in thousands), 2007	33
Table 2.5:	Forecast epidemiology of dyslipidemia across the seven major markets (in thousands), 2007–2013	34
Table 2.6:	Estimated prevalence of stroke across the seven major markets (in thousands), 2007	38
Table 2.7:	Forecast epidemiology of stroke across the seven major markets (in thousands), 2007–2013	39

Table 3.8:	The global cardiovascular market by drug class (\$m), 2006–2007	46
Table 3.9:	Leading brands in the global cardiovascular market (\$m), 2006–2007	48
Table 3.10:	Cardiovascular market sales forecast by drug class (\$m), 2007–2013	49
Table 3.11:	Leading anti-hypertensives treatments in the global cardiovascular market (\$m), 2006–2007	57
Table 3.12:	Anti-hypertensives sales forecast (\$m), 2007–2013	62
Table 3.13:	Leading anti-dyslipidemic treatments in the global cardiovascular market (\$m), 2006–2007	65
Table 3.14:	Anti-dyslipidemics sales forecast (\$m), 2007–2013	72
Table 3.15:	Leading anti-thrombotics treatments in the global cardiovascular market (\$m), 2006–2007	76
Table 3.16:	Anti-thrombotics sales forecast (\$m), 2007–2013	80
Table 3.17:	Leading hematological preparations in the global cardiovascular market (\$m), 2006–2007	83
Table 3.18:	Hematological preparations sales forecast (\$m), 2007–2013	85
Table 3.19:	Leading cardiac therapies in the global cardiovascular market (\$m), 2006–2007	88
Table 3.20:	Cardiac therapies sales forecast (\$m), 2007–2013	89
Table 3.21:	Other cardiovascular treatments in the global cardiovascular market (\$m), 2006–2007	91
Table 3.22:	Cardiovascular treatments sales forecast (\$m), 2007–2013	93
Table 4.23:	An overview of Letairis	107
Table 4.24:	An overview of Tekturna/Rasilez	108
Table 4.25:	An overview of Effient	110
Table 4.26:	An overview of Multaq	111
Table 4.27:	An overview of Xarelto	113
Table 4.28:	An overview of TriLipix	114
Table 4.29:	An overview of Pradaxa	116
Table 4.30:	An overview of Apixaban	117
Table 4.31:	An overview of Cangrelor	119
Table 4.32:	An overview of SCH530348	120
Table 4.33:	An overview of Ticagrelor	122
Table 4.34:	An overview of E5555	123
Table 4.35:	Cardiovascular disorders pipeline forecast, (\$m), 2008–13	125
Table 5.36:	Leading Players in the global cardiovascular market, (\$m),	129
Table 5.37:	Pfizer's leading cardiovascular product portfolio, (\$m), 2006–07	135
Table 5.38:	Pfizer's cardiovascular R&D product pipeline, 2007	139
Table 5.39:	Sanofi-Aventis' leading cardiovascular product portfolio, (\$m), 2006–07	144
Table 5.40:	Sanofi-Aventis' cardiovascular R&D product pipeline, 2007	148
Table 5.41:	Merck's leading cardiovascular product portfolio, (\$m), 2006–07	152
Table 5.42:	Merck's cardiovascular R&D product pipeline, 2007	154
Table 5.43:	Novartis' leading cardiovascular product portfolio, (\$m), 2006–07	158
Table 5.44:	Novartis' cardiovascular R&D product pipeline, 2007	160
Table 5.45:	Amgen's cardiovascular R&D product pipeline, 2007	163
Table 5.46:	AstraZeneca's leading cardiovascular product portfolio, (\$m), 2006–07	168
Table 5.47:	AstraZeneca's cardiovascular R&D product pipeline, 2007	170
Table 5.48:	BMS's leading cardiovascular product portfolio, (\$m), 2006–07	174
Table 5.49:	BMS's cardiovascular R&D product pipeline, 2007	176
Table 5.50:	J&J's leading cardiovascular product portfolio, (\$m), 2006–07	179
Table 5.51:	J&J's cardiovascular R&D product pipeline, 2007	180
Table 5.52:	Daiichi Sankyo's leading cardiovascular product portfolio, (\$m),	183
Table 5.53:	Daiichi Sankyo's cardiovascular R&D product pipeline, 2007	184
Table 5.54:	GSK's leading cardiovascular product portfolio, (\$m),	188
Table 5.55:	GSK's cardiovascular R&D product pipeline, 2007	189

